Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Unresectable Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Jun Zhou) · Joelbmu@126.com · 13366152815

Study leads

Jun Zhou
Principal Investigator
Peking University Cancer Hospital & Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Carcinoma, Hepatocellular · Hepatocellular Cancer · Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Los Angeles, United States

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Hepatocellular Carcinoma · Hepatocellular Cancer · Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Seoul, South Korea

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma · Immune Checkpoint Inhibitors · Anti-angiogenic Therapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Munich, Germany · Munich, Germany